Oncology
Starve solid tumors
Anti-angiogenic biologics designed to disrupt the vasculature that feeds aggressive cancers.
Vascular biology · Research stage
Engineering the repair environment through localized angiogenic signaling.
AngioPatch™ is a research-stage platform concept designed to support controlled vascular signaling where damaged tissue needs it most.
Proposed mechanismAP / 01
01Damaged tissue
02AngioPatch™
03Localized signaling
04Vascular support
05Repair environment
Research-stage platform model · Local delivery · Controlled biological signaling
1
Research-stage platform
5
Potential application areas
6
Validation milestones planned
$15.7B
2024 market opportunity
Biological premise
Tumors need a blood supply. We cut it off.
Angiogenesis — the formation of new blood vessels from existing vasculature — is a normal process in growth and healing. When hijacked by disease, it enables tumor growth, vision loss, and chronic inflammation.
Our platform builds bispecific biologics that target the VEGF pathway with greater precision and durability than current standards of care. The same chemistry, inverted, can also promote healing in ischemic heart tissue.
Platform thesis
One biological system. Three therapeutic contexts.
Ophthalmology
Preserve vision
Durable inhibitors for wet AMD and diabetic retinopathy — fewer injections, longer effect.
Cardiovascular
Restore perfusion
Pro-angiogenic agents to rebuild capillary networks after ischemic injury.
Research & partnership
Building the future of vascular medicine.
Request our investor packet, or get in touch about clinical and research partnerships.